2002/042 Photodynamic therapy for age-related macular degeneration
Issued: 25th July 2002
NICE announced today that the timeline for its appraisal of photodynamic therapy for age-related macular degeneration is being extended to allow further consideration of the draft guidance.
Anne-Toni Rodgers, Communication Director and executive lead for this appraisal said: "The independent committee that advises NICE follows a consultative process for the development its guidance. The second document it produces, is a Final Appraisal Determination, often referred to as a FAD.
"The FAD for this appraisal proposed guidance that relied on the existence of a nationally organised data collection exercise. When the FAD was formulated, the Institute's chief executive, Andrew Dillon, wrote to the Department of Health and the Welsh Assembly Government asking them to investigate the establishment of this data collection exercise. The response we have received indicates that there is little prospect of national sponsorship for the arrangement we proposed.
"In the circumstances, we have no choice other than to ask the Appraisal Committee to reconsider the evidence in the light of this new information."
"The independent Appraisal Committee will meet on the 12 September to reconsider the FAD alongside this new information. Following this meeting we will issue a further consultation document, which will be made available on the NICE web site. The results of this consultation will be considered by the Appraisal Committee on 13 November and the earliest guidance will be issued to the NHS is January 2003.
"I very much regret this extension of the timeline for this appraisal, but as you will appreciate, it is essential that the NHS can implement the guidance NICE issues."
This page was last updated: 30 March 2010